Virtual Library
Start Your Search
Jose Miguel Jurado-Garcia
Author of
-
+
P3.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 983)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 2
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.17-16 - Adenocarcinoma or Epidermoid? The Importance of the Histological Subdivision (ID 11275)
12:00 - 13:30 | Author(s): Jose Miguel Jurado-Garcia
- Abstract
Background
Lung cancer is the leading cause of cancer death. Most studies focus on metastatic disease, and the complementary treatment in localized disease has limited evidence. This study aims to highlight the factors that influence the survival of lung cancer in localized phase.
a9ded1e5ce5d75814730bb4caaf49419 Method
A retrospective study was conducted on 96 patients (14% women and 86% men, median age of 66 years) with localized lung cancer treated in our center between 2009 and 2017. At the end of the data collection, 44 patients had died (46 %) but 52 (54%) remained alive until today. All the medical histories were reviewed in order to analyze different parameters related to histology, stage, tumor biology, imaging tests, surgery and treatment. A statistical data analysis software (SPSS) was applied to find statistically significant relationships between the variables.
4c3880bb027f159e801041b1021e88e8 Result
From the 49 patients with adenocarcinoma, 18 (37% of the total) died with a median overall survival (OS) of 35 months (27-43 months with CI <0.05%). From the 47 epidermoids, 26 died (55% of the total) although with a median OS of 59 months (40-78 months with CI <0.05%).
By stages I and II: The median OS for the adenocarcinoma group was 12.33 months (3.6-21 months with CI <0.05%) versus the squamous cell group, with a median of 28.75 months (12.6-57, 8 months with CI <0.05%).
Between stages III: The median OS in the adenocarcinoma group was 14 months (11.7-16.2 months with CI <0.05%) compared to the squamous group with 22.26 months (15.7-28.8 months with CI <0.05% ).
The median OS among the patients with some inflammation data was 65.7 months (57-74 months with CI <0.05%).
8eea62084ca7e541d918e823422bd82e Conclusion
Adenocarcinomas seem to present a worse prognosis in localized stage, in contrast to metastatic stage.
Inflammation seem to play an important role in the evolution of the tumor, regardless of the treatment.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P3.17-17 - Stage III: Analysis to Assist in the Decision of Surgery Against Quimio-Radiotherapy (ID 13515)
12:00 - 13:30 | Author(s): Jose Miguel Jurado-Garcia
- Abstract
Background
The treatment of localized stage lung cancer offers limited succes in terms of increase survival. This study aims to find out if there are differences in disease-free survival (DFS) between surgery and chemo-radiotherapy in lung cancer Stage III.
a9ded1e5ce5d75814730bb4caaf49419 Method
A retrospective study was conducted on 96 patients with localized lung cancer treated in our center between from 2009 to and 2017, selecting only patients in Stage III. All the clinical medical histories were reviewed in order to analyze different parameters related to demography, histology and treatment. A statistical data analysis software (SPSS) was applied to search for relationships statistically significant among the variables. For the survival analysis, They used Kaplan-Meier curves and the Log-Rank test.
4c3880bb027f159e801041b1021e88e8 Result
39 cases of patients in Stage III were collected.
The surgery group (with neoadjuvant or adjuvant chemotherapy) covers 21 patients (54%). The group treated with Chemo-Radiotherapy includes 18 patients (46%).
For the surgery group, the mean for the DFS is estimated at 51 months (39.5-62.3 months), the median has not yet been reached.The mean DFS in the Chemo-Radiotherapy group is 40.2 months (22.6-57.8 months); the median being 18.2 months (15.75-20.65 months). These differences are statistically significant.
The group treated with surgery: median age of 66.5 years, 94% male smokers. The adenocarcinoma represented the 61% of the group compared to the epidermoids, which account for 39%. In 44% of the tumors, signs of inflammatory infiltration were found. The Standard Uptake Value (SUV) average was 11.19 (2.72-18 SUV).
The group treated with Chemo-Radiotherapy: median age of 66 years, 95% male smokers, 57% epidermoid tumors versus 43% of adenocarcinomas. Only 14% had signs of histological inflammation. The average SUV was 15.94 (3-48 SUV).
8eea62084ca7e541d918e823422bd82e Conclusion
Patients candidates for surgery not only have optimal respiratory function tests. They seem to present less pulmonary pathology, a better immune response against tumors and a lower SUV value.
6f8b794f3246b0c1e1780bb4d4d5dc53
